Resources from the same session
1001MO - Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation
Presenter: Martin Wermke
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast